Author: Fleischmann, Roy

Source: Aging Health, Volume 2, Number 2, April 2006 , pp. 189-197(9)

Publisher: Future Medicine

Abstract:

Recent advances in the understanding of the pathophysiology and aggressive treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis have dramatically changed the outcomes of patients with these diseases over the past 7 years. Much of the progress in therapy is due to the change in the treatment paradigm in which early, aggressive therapy has become the norm and the introduction of therapies that target the disease processes, specifically the overproduction of tumor necrosis factor-α. Etanercept was the first anti-tumor necrosis factor-α therapy approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. It has been shown to have an excellent risk:benefit ratio in clinical trials as well as postmarketing surveillance. However, there has been limited information regarding the safety and efficacy of etanercept in patients aged 65 years or over, which is the focus of this review.

Keywords: ankylosing spondylitis; anti-tumor necrosis factor; etanercept; juvenile arthritis; psoriatic arthritis; rheumatoid arthritis

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.2217/1745509X.2.2.189

Affiliations: 1: University of Texas Southwestern Medical Center at Dallas, Co-Medical Director Radiant Research – Dallas, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235-5360 USA., Email: royfleischmann@radiantresearch.com

Publication date: 2006-04-01

More about this publication?

• Aging Health leading coverage of current and emerging topics relating to the safe and effective management of therapy in the elderly, all subject to rigorous peer review. The journal focuses on the most important advances and highlights their relevance in the clinical setting. The journal has been designed to deliver essential concise information in an easily assimilable format - vital for the increasingly time-constrained professional.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• E-Access Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General) ,  Nursing
• By this author: Fleischmann, Roy

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers